MedTrace Logo

HD17 for Intermediate Stage Hodgkin Lymphoma

NCT01356680 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1100

Last updated 2020-04-06

No results posted yet for this study

Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

Conditions

Interventions

DRUG

BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)

DRUG

ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)

RADIATION

30Gy IF-RT (Involved-Field Radiotherapy)

RADIATION

30Gy IN-RT (Involved-Node Radiotherapy)

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Andreas Engert, Prof. · University of Cologne, German Hodgkin Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-13
Primary Completion
2020-03-21
Completion
2020-03-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01356680 on ClinicalTrials.gov